Mutational analysis of epidermal and hyperproliferative type I keratins in mild and moderate psoriasis vulgaris patients: a possible role in the pathogenesis of psoriasis along with disease severity

[1]  Gang Wang,et al.  TGFβ/SMAD/microRNA-486-3p Signaling Axis Mediates Keratin 17 Expression and Keratinocyte Hyperproliferation in Psoriasis. , 2017, The Journal of investigative dermatology.

[2]  Y. Poulin,et al.  Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  Yueqiu Tan,et al.  [Study of a family with epidermolysis bullosa simplex resulting from a novel mutation of KRT14 gene]. , 2017, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

[4]  Ceren Sucularlı,et al.  Computational prediction and analysis of deleterious cancer associated missense mutations in DYNC1H1. , 2017, Molecular and cellular probes.

[5]  K. Zeng,et al.  S159P mutation of keratin 10 gene causes severe form of epidermolytic hyperkeratosis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  Yang Zhang,et al.  STRUM: structure-based prediction of protein stability changes upon single-point mutation , 2016, Bioinform..

[7]  Lin‐feng Li,et al.  Ichthyosis hystrix Lambert type and Curth-Macklin type are a single entity with affected (KRT1 mutation) or unaffected (KRT10 mutation) palms and soles? , 2016, European Journal of Dermatology.

[8]  A. Thirupathi,et al.  Methotrexate normalized keratinocyte activation cycle by overturning abnormal keratins as well as deregulated inflammatory mediators in psoriatic patients. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[9]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[10]  Glenn A. Maston,et al.  A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders , 2015, Human mutation.

[11]  G. Dreissen,et al.  Distinct Impact of Two Keratin Mutations Causing Epidermolysis Bullosa Simplex on Keratinocyte Adhesion and Stiffness. , 2015, The Journal of investigative dermatology.

[12]  G. Pellacani,et al.  Management of Patients with Psoriasis Treated with Biological Drugs Needing a Surgical Treatment , 2014, Drug development research.

[13]  Yun Bai,et al.  Mutation p.Leu128Pro in the 1A domain of K16 causes pachyonychia congenita with focal palmoplantar keratoderma in a Chinese family , 2014, European Journal of Pediatrics.

[14]  Jaroslav Bendl,et al.  PredictSNP: Robust and Accurate Consensus Classifier for Prediction of Disease-Related Mutations , 2014, PLoS Comput. Biol..

[15]  Gang Wang,et al.  Keratin 17 as a therapeutic target for the treatment of psoriasis. , 2012, Journal of dermatological science.

[16]  P. Coulombe,et al.  Keratin 16 null mice develop palmoplantar keratoderma, a hallmark feature of pachyonychia congenita and related disorders , 2011, The Journal of investigative dermatology.

[17]  Dipal M. Patel,et al.  Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis , 2011, Nature Reviews Molecular Cell Biology.

[18]  C. Griffiths,et al.  Definition of treatment goals for moderate to severe psoriasis: a European consensus , 2010, Archives of Dermatological Research.

[19]  E. Lane,et al.  ERK involvement in resistance to apoptosis in keratinocytes with mutant keratin. , 2010, The Journal of investigative dermatology.

[20]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[21]  A. Knight,et al.  A novel mutation (p.Thr198Ser) in the 1A helix of keratin 5 causes the localized variant of Epidermolysis Bullosa Simplex , 2009, Experimental dermatology.

[22]  M. Omary,et al.  Toward unraveling the complexity of simple epithelial keratins in human disease. , 2009, The Journal of clinical investigation.

[23]  Gonçalo Abecasis,et al.  Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis , 2009, Nature Genetics.

[24]  Wei Huang,et al.  Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21 , 2009, Nature Genetics.

[25]  E. Lane,et al.  The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases , 2008, Human mutation.

[26]  P. Coulombe,et al.  Intermediate filament scaffolds fulfill mechanical, organizational, and signaling functions in the cytoplasm. , 2007, Genes & development.

[27]  J. Uitto,et al.  Diseases of epidermal keratins and their linker proteins. , 2007, Experimental cell research.

[28]  R. Leube,et al.  Structural and regulatory functions of keratins. , 2007, Experimental cell research.

[29]  H. Winter,et al.  Hair follicle-specific keratins and their diseases. , 2007, Experimental cell research.

[30]  F. Wald,et al.  Intermediate filaments: a role in epithelial polarity. , 2007, Experimental cell research.

[31]  P. V. D. van de Kerkhof,et al.  Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis , 2006, The British journal of dermatology.

[32]  E. Birgitte Lane,et al.  New consensus nomenclature for mammalian keratins , 2006, The Journal of cell biology.

[33]  P. Coulombe,et al.  A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth , 2006, Nature.

[34]  J. Segre,et al.  Epidermal barrier formation and recovery in skin disorders. , 2006, The Journal of clinical investigation.

[35]  M. Madsen,et al.  Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 21 , 2006, The Journal of Immunology.

[36]  Arlo Z. Randall,et al.  Prediction of protein stability changes for single‐site mutations using support vector machines , 2005, Proteins.

[37]  Piero Fariselli,et al.  I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure , 2005, Nucleic Acids Res..

[38]  J. Reichelt,et al.  Loss of keratin 10 leads to mitogen-activated protein kinase (MAPK) activation, increased keratinocyte turnover, and decreased tumor formation in mice. , 2004, The Journal of investigative dermatology.

[39]  E. Lane,et al.  Keratins and skin disorders , 2004, The Journal of pathology.

[40]  M. Vaidya,et al.  Implications of cytokeratin 8/18 filament formation in stratified epithelial cells: Induction of transformed phenotype , 2004, International journal of cancer.

[41]  F. Smith.  Nail that mutation-keratin 17 defect in late-onset pachyonychia. , 2004, The Journal of investigative dermatology.

[42]  E. Lane,et al.  Phenotypes, genotypes and their contribution to understanding keratin function. , 2003, Trends in genetics : TIG.

[43]  Hans Scheffer,et al.  Mutation analysis of the entire keratin 5 and 14 genes in patients with epidermolysis bullosa simplex and identification of novel mutations , 2003, Human mutation.

[44]  E. Lane,et al.  Keratin mutations of epidermolysis bullosa simplex alter the kinetics of stress response to osmotic shock , 2002, Journal of Cell Science.

[45]  J. Reichelt,et al.  Hyperproliferation, induction of c-Myc and 14-3-3sigma, but no cell fragility in keratin-10-null mice. , 2002, Journal of cell science.

[46]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[47]  D. Roop,et al.  Deregulated expression of c-Myc depletes epidermal stem cells , 2001, Nature Genetics.

[48]  L. Milstone,et al.  Delayed‐onset pachyonychia congenita associated with a novel mutation in the central 2B domain of keratin 16 , 2001, The British journal of dermatology.

[49]  Fiona M Watt,et al.  c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny , 2001, Current Biology.

[50]  J. Uitto,et al.  Novel keratin 16 mutations and protein expression studies in pachyonychia congenita type 1 and focal palmoplantar keratoderma , 2000, Experimental dermatology.

[51]  E. Papadavid,et al.  Generalized pustular psoriasis developing during withdrawal of short‐term cyclosporin therapy , 2000, The British journal of dermatology.

[52]  I. Leigh,et al.  Novel and recurrent mutations in keratin 10 causing bullous congenital ichthyosiform erythroderma , 1999, Experimental dermatology.

[53]  P. Van Erp,et al.  Proliferation is the main epidermal target in the treatment of psoriatic plaques with once daily application of tacalcitol ointment. , 1999, Acta dermato-venereologica.

[54]  E. Fuchs,et al.  A structural scaffolding of intermediate filaments in health and disease. , 1998, Science.

[55]  E. Lane,et al.  Missense mutations in keratin 17 cause either pachyonychia congenita type 2 or a phenotype resembling steatocystoma multiplex. , 1997, The Journal of investigative dermatology.

[56]  H. Scheffer,et al.  Effects of keratin 14 ablation on the clinical and cellular phenotype in a kindred with recessive epidermolysis bullosa simplex. , 1996, The Journal of investigative dermatology.

[57]  P. Coulombe,et al.  Onset of re-epithelialization after skin injury correlates with a reorganization of keratin filaments in wound edge keratinocytes: defining a potential role for keratin 16 , 1996, The Journal of cell biology.

[58]  P. V. D. van de Kerkhof,et al.  Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. , 1995, Journal of dermatological science.

[59]  E. Lane,et al.  Keratin 16 and keratin 17 mutations cause pachyonychia congenita , 1995, Nature Genetics.

[60]  E. Lane,et al.  A functional "knockout" of human keratin 14. , 1994, Genes & development.

[61]  E. Fuchs,et al.  A human keratin 14 "knockout": the absence of K14 leads to severe epidermolysis bullosa simplex and a function for an intermediate filament protein. , 1994, Genes & development.

[62]  E. Fuchs,et al.  Genetic mutations in the K1 and K10 genes of patients with epidermolytic hyperkeratosis. Correlation between location and disease severity. , 1994, The Journal of clinical investigation.

[63]  P. Cacoub,et al.  LIFE-THREATENING PSORIASIS RELAPSE ON WITHDRAWAL OF CYCLOSPORIN , 1988, The Lancet.

[64]  M. Osborn.  Intermediate filaments as histologic markers: an overview. , 1983, The Journal of investigative dermatology.

[65]  Elaine Fuchs,et al.  Changes in keratin gene expression during terminal differentiation of the keratinocyte , 1980, Cell.

[66]  P. Elwood,et al.  Milk antibodies and myocardial infarction [Letter] , 1974 .

[67]  Bing Yu,et al.  Mutation surveyor: an in silico tool for sequencing analysis. , 2011, Methods in molecular biology.

[68]  Z. Tulassay,et al.  Easy method for keratin 14 gene amplification to exclude pseudogene sequences: new keratin 5 and 14 mutations in epidermolysis bullosa simplex. , 2009, The Journal of investigative dermatology.

[69]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[70]  H. Bovenschen,et al.  In vivo effects of topical anti-psoriatic treatments on cutaneous inflammation, epidermal proliferation and keratinisation. , 2007 .

[71]  D. Hohl,et al.  Altered distribution of keratinization markers in epidermolytic hyperkeratosis , 2005, Archives of Dermatological Research.

[72]  D. Mischke,et al.  Normal psoriatic epidermis expression of hyperproliferation-associated keratins , 2004, Archives of Dermatological Research.

[73]  F. Ramaekers,et al.  Keratin 17: a useful marker in anti-psoriatic therapies , 2004, Archives of Dermatological Research.